Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Vir Biotechnology, Inc.

< Previous 1 2 Next >
Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.